A pharmacy slip, a discharge sheet, or a refill text that says insulin lispro is not a different drug from Humalog. It is the same drug under its generic name. Knowing that second name gets you the right box at the counter.
This guide covers where the name Humalog comes from, what the words on a label mean, and how to read a box printed with the generic name instead. It also covers the part worth getting right: a name change on a box is a fact about packaging, not permission to change how you inject.
Nothing here is medical advice. Your prescriber or pharmacist decides anything about your insulin.
In this guide
- Two names, one medicine
- Where insulin lispro comes from
- Three facts about the molecule
- The forms that carry the lispro name
- When the box says lispro and no brand
- Where the four-letter suffix comes from
- A second company’s insulin lispro
- How to read a label that uses either name
- Where a swap becomes a real decision
- Questions people ask
- What to take away
Two names, one medicine
Humalog is a brand name, and Eli Lilly and Company owns it. Insulin lispro is the generic name for the molecule, and it is the name a pharmacist types into the system.
The HUMALOG prescribing information on DailyMed opens with both in one line: “HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use.” The same line carries a date, Initial U.S. Approval: 1996, which explains much of the confusion people run into.
That is early for an insulin, and the timing matters. Every insulin on the market was reclassified as a biologic in March 2020 under the Biological Price Competition and Innovation Act. Insulin approved long before that date carries no four-letter suffix, because it already had a plain generic name. Humalog has been insulin lispro since 1996.
So the answer to “another name for Humalog” is short. Insulin lispro is the other name. The rest of this article is detail about what that name covers.
Where insulin lispro comes from
A company sells one product under one brand name. Eli Lilly wanted insulin that absorbed faster, so it built a slightly different molecule.
Human insulin is a chain of amino acids. In the version Lilly engineered, the two at positions 28 and 29 of the B chain swapped places. The label states it plainly: proline at B28 is replaced by lysine, and lysine at B29 by proline. Chemically it is Lys(B28), Pro(B29) human insulin.
The swap exists for a reason about absorption. Regular human insulin clumps after injection, and those clumps must break apart before insulin reaches the bloodstream. That wait is why regular insulin needs a lead time before meals. Insulin lispro does not clump the same way, so it enters the blood faster and does not last as long. That is why the label calls it a rapid-acting analog.
One point follows, and it matters at the counter. The generic name describes the molecule, not the package. Two products with the same generic name hold the same molecule, but one may carry handling rules the other does not.
Three facts about the molecule
It is made in a laboratory, not taken from a person or an animal. The label says insulin lispro is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli. MedlinePlus describes it as a biologic medication, made from living organisms.
It is the same size as human insulin. The molecular weight and empirical formula on the label match those of human insulin. Only the order of two amino acids differs. That is the idea behind an analog. It is a small edit, not a new substance.
It handles meals, not the background. It lowers the rise in blood sugar after eating. The Humalog label says it is generally used in regimens with an intermediate-acting or long-acting insulin. A mealtime insulin does not supply the background your body is missing.
The forms that carry the lispro name
Naming gets tangled here. Read the generic line on the box.
| What the box says | What it is |
|---|---|
| HUMALOG (insulin lispro) injection, U-100 | The rapid-acting analog, clear solution, in a 10 mL vial, a 3 mL vial, or several prefilled pens |
| HUMALOG (insulin lispro) injection, U-200 | The same molecule at twice the concentration, available only as a prefilled pen |
| HUMALOG MIX75/25 | Insulin lispro protamine plus insulin lispro, a cloudy suspension approved in 1999 |
| HUMALOG MIX50/50 | The same two-part mixture at an even split, also approved in 1999 |
| LYUMJEV (insulin lispro-aabc) injection | The same molecule reformulated to absorb faster, approved in 2020 |
A vial and a prefilled pen hold the same medicine in different packaging. A vial is drawn up with a syringe, and a pen has the dose dialed on. The label says the dose window shows the units being delivered and that no conversion is needed.
The U-200 pen is different, and the difference lives on the box rather than in the molecule. The label says U-200 must not be mixed with any other insulin and must not go in a pump. It also must not be transferred into a syringe, because syringe markings will not measure it correctly. Those rules exist because that package holds a higher concentration.
The two Humalog mixtures are not plain lispro. HUMALOG MIX75/25 is labeled “insulin lispro protamine and insulin lispro injectable suspension,” a mixture of an intermediate-acting part and a rapid-acting part. It is a cloudy suspension for adults, and the label says not to give it intravenously or through a pump. A Mix75/25 box is not a plain lispro box, and the label’s warnings about insulin mix-ups are written for that error.
When the box says lispro and no brand
This is the situation that sends people searching for another name. DailyMed carries an Eli Lilly label titled INSULIN LISPRO injection, solution with no brand in the product name and the same 1996 approval date. Its first administration instruction reads “This product is HUMALOG (insulin lispro).”
That sentence settles the question for most people who ask it.
Neither that label nor this article needs to settle what the manufacturer calls it. What the label proves is narrower and more useful: a product with no brand on it can still be the same lispro molecule, and this one says so in plain words.
Two details on that listing are worth a second look. Its product information block names the active ingredient as insulin lispro with a chemical identifier, which is how a label names a substance, not a product. Its pump instructions are phrased in Humalog terms, saying the product can be used with pumps labeled for Humalog. Whether a product suits a pump depends on that pump’s labeling, not only on the molecule. If your pump manual lists Humalog, the unbranded label points at the same manual.
Repackagers widen the pattern. A DailyMed search for insulin lispro returns 16 label entries, several from companies that distribute or relabel drugs without making the insulin. Those entries carry the generic name only.
Where the four-letter suffix comes from
The FDA requires biological products to carry a nonproprietary name built from a core name plus four lowercase letters with no meaning of their own. The suffix lets a report about one insulin be told apart from a report about another.
Insulin lispro-aabc is the only lispro product using one. Its brand is Lyumjev, approved in 2020. Its label describes the same B28 and B29 swap and the same molecular weight as human insulin. The difference sits in the formulation, which adds treprostinil sodium and sodium citrate dihydrate as inactive ingredients.
One naming detail trips people up. The label prints four letters, aabc. Shortened three-letter forms such as insulin lispro-aab turn up in secondary writing and in search boxes. Every primary source checked for this article prints four. The original FDA approval document for Lyumjev prints four letters in every one of its 37 occurrences of the name. The Purple Book proper name for the product is four letters, and the National Library of Medicine’s terminology database returns that same name with no three-letter product at all. If you see three letters, the shortening happened upstream of the label.
A second company’s insulin lispro
Humalog is not the only product with that generic name. ADMELOG, from sanofi-aventis U.S. LLC, carries insulin lispro too and was first approved in 2017. Its label uses the same rapid-acting analog wording, and it comes as vials and prefilled pens.
That raises a question people rarely ask, which is what category that product falls into. Insulin lispro products sit in categories such as biosimilars and products designated interchangeable for pharmacy substitution. Which category fits a given product depends on when it was approved and on the state you live in. The primary labels do not use those category words, so a label will not settle it for your box. Ask the pharmacist what your product is and what your pharmacy may substitute.
How to read a label that uses either name
Four checks, in the order that works at a counter.
- Read the generic line, not the brand line. It is the phrase in parentheses after the brand name, or the whole name when there is no brand. On Humalog it reads insulin lispro. On a no-brand box it reads insulin lispro. On a mixture it names two, lispro protamine and lispro.
- Check whether it says solution or suspension. A clear solution and a cloudy suspension are different products with different rules. The Humalog mixtures are suspensions, and their labels keep them out of pumps.
- Check the concentration line, U-100 or U-200. This is the part that changes what you may do with the pen. The rules for U-200 are stricter, and they travel with the box rather than the molecule.
- Have the pharmacist read the NDC number back to you. That code on the carton identifies exactly which product you are holding, and it settles a mismatch faster than anything else you could say.
Two habits from the labels are worth building. The Humalog label says to check the label before every injection, because mix-ups between insulin products are a known cause of serious errors. It also says never to share a pen, cartridge, or syringe between people.
Where a swap becomes a real decision
Nothing here tells you to change anything. The labels are direct about why they leave that to a reader.
The Humalog label says that when switching from another insulin to Humalog, a different dosage may be needed. Changes to strength, manufacturer, type, injection site, or method of administration may all affect blood sugar control. Any change belongs under close medical supervision with more frequent monitoring.
MedlinePlus puts the same rule in plain language for patients. Do not switch to another brand or type of insulin, and do not change the dose of any insulin you use, without talking to your doctor.
Read that as a list of decisions, not one. Moving from Humalog to an unbranded insulin lispro keeps the molecule. It may still change the device you use, the concentration, and whether your pump is cleared for it. Moving from insulin lispro to insulin lispro-aabc changes the formulation instead. Moving from either to another rapid-acting analog, such as insulin aspart or insulin glulisine, changes the molecule outright.
None of that is yours to work out from a label. Ask your prescriber or pharmacist to make the change, say when to start, and tell you what to watch while your body adjusts.
Questions people ask
Is insulin lispro the same as Humalog?
Yes. The label reads “HUMALOG (insulin lispro) injection,” and the unbranded Lilly product says “This product is HUMALOG (insulin lispro).” Either name identifies the same molecule.
What is Humalog called generically?
Insulin lispro, written out on the label as insulin lispro injection. Older label formats add USP and rDNA origin.
Is insulin lispro-aabc the same as Humalog?
Same molecule, different formulation. Its label describes the same amino acid swap and the same molecular weight as human insulin, and the difference is in the inactive ingredients added to speed absorption. Its brand is Lyumjev, with its own mealtime timing and its own pump and concentration rules.
Why does my box have no brand on it?
Because it is sold under the generic name. An unbranded insulin lispro product still lists insulin lispro as the active ingredient and still identifies itself on the label. Your pharmacist can confirm yours against the NDC code.
Is Humalog 70/30 the same as insulin lispro?
Not reliably, so check it carefully. Humalog’s lispro mixtures are Mix75/25 and Mix50/50, and both contain lispro plus lispro protamine. Humalog 70/30 has a separate history, and I could not confirm from a primary source what its label says today. Raise any Humalog 70/30 box with your pharmacist rather than assuming.
Can I switch from Humalog to generic insulin lispro on my own?
No. Insulin lispro is regulated as a biologic, and substitution between biologics depends on the product and on state law. MedlinePlus says not to switch brands or types of insulin without talking to your doctor, and the Humalog label says regimen changes belong under medical supervision.
Does the name change how fast it works?
No. Insulin lispro and insulin lispro-aabc share a molecule and a molecular weight. The speed difference between them comes from the formulation, and each product’s label describes its own mealtime window.
Is insulin lispro the same as insulin aspart or glulisine?
No. Those are different analogs with different amino acid changes and different brands, NovoLog and NovoRapid for aspart, Apidra for glulisine. All are rapid-acting, and moving between them is a prescriber decision.
What to take away
Humalog is the brand, and insulin lispro is the generic name for the same drug, a rapid-acting human insulin analog first approved in 1996. The name shows up on vials, on prefilled pens, and on packages with no brand at all. Eli Lilly sells an unbranded insulin lispro product whose label says outright that it is Humalog, and Sanofi sells another under its own brand. Three nearby names cause most of the confusion.
Mix75/25 and Mix50/50 are lispro plus lispro protamine mixtures, not plain lispro. Insulin lispro-aabc is the same molecule reformulated to absorb faster, sold as Lyumjev, and the label prints four letters after lispro. And a U-200 box carries handling rules of its own.
When a box and your expectation do not match, one sentence to your pharmacist settles most of it: read me the generic name and the NDC code. Leave any decision about switching, timing, or dosing to your prescriber.